SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Endocr Disord
Main Authors: Schernthaner, Guntram, Drexel, Heinz, Moshkovich, Evgeny, Zilaitiene, Birute, Martinka, Emil, Czupryniak, Leszek, Várkonyi, Tamás, Janež, Andrej, Ducena, Kristine, Lalić, Katarina, Tankova, Tsvetalina, Prázný, Martin, Smirčić Duvnjak, Lea, Sukhareva, Olga, Sourij, Harald
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Correspondence
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6580491/
https://ncbi.nlm.nih.gov/pubmed/31208401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-019-0387-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados